More Data on Finerenone for Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Secondary analyses of FINEARTS-HF address concerns about a sex-based effect difference and repercussions of increased serum potassium.

The FINEARTS-HF trial demonstrated that mineralocorticoid receptor antagonists (MRAs) effectively treat heart failure (HF) with preserved or mildly reduced ejection fraction (EF; NEJM JW Cardiol Sep 4 2024 and N Engl J Med 2024; 391:1475). However, concerns remain as to whether MRAs work similarly well in men and women, and whether increased serum potassium levels potentially limit their use. Secondary analyses address these issues.

A sex-specific analysis among the 6000 trial participants revealed many expected differences between women and men in terms of clinical presentation and symptoms. Women had higher EF, worse functional class, and poorer self-reported health status. Also, comorbidities varied by sex (e.g., more coronary heart disea…

Reviewing Author

Vlad G. Zaha, MD, PhD, FACC, FAHA

Disclosures

Grant/Research SupportCancer Prevention and Research Institute of Texas; National Institute of Health

Editorial BoardsCirculation

Leadership Positions in Professional SocietiesTexas Chapter of the American College of Cardiology (Section Chair, Cardio-Oncology)

Vlad G. Zaha, MD, PhD, FACC, FAHA

Disclosures

Grant/Research SupportCancer Prevention and Research Institute of Texas; National Institute of Health

Editorial BoardsCirculation

Leadership Positions in Professional SocietiesTexas Chapter of the American College of Cardiology (Section Chair, Cardio-Oncology)

More Data on Finerenone for Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Topics

Reviewing Author